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Colorectal cancer is one of the most common cancers worldwide, with nearly 1.4 million cases and over 690 000 deaths estimated to have occurred in 2012 [1] . Although improvements in early detection and medical treatment have increased cure rates, distant metastasis is still the leading cause of death for patients with colorectal cancers [2, 3] . Thus, the investigation of the processes and molecular mechanisms underlying colorectal cancer metastasis is critical for developing effective diagnostic and therapeutic approaches.
The epithelial-mesenchymal transition (EMT) is a result of the accumulation of genetic aberrations and epigenetic alterations, and EMT is presumed to be a crucial step in initiating cancer metastasis [4] [5] [6] [7] . Tumor cells transiently lose their epithelial characteristics and acquire mesenchymal characteristics, which leads to enhanced motility, invasion potential, and metastasis. Recently, many cancer-associated glycans and genes involved in glycan synthesis ('glycogenes') were shown to contribute in EMT of cancer cells [8] [9] [10] [11] . For instance, the genes encoding the glycosyltransferases ST8SIA1 and B4GALNT1, which are strongly induced upon EMT in breast cancer cells, are involved in the induction of the expression of tumor-associated Abbreviations bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; EMT, epithelial-mesenchymal transition; miRNA, microRNA; RISC, RNAinduced silencing complex; TGFb, tumor growth factor b.
gangliosides, GD2 and GD3, and they contribute to enhanced cell motility and mammosphere formation [8, 9] . We previously showed that the glycogenes ST3GAL1/3/4 are induced upon EMT, with consequent enhanced expression of selectin-binding glycans on the cell surface of cancer cells, which facilitates hematogenous metastasis [10] . FUT8, another glycogene encoding a fucosyltransferase, is known to be upregulated during EMT, and its disruption inhibits their malignant behaviors, including in vitro invasion and cell proliferation as well as in vivo metastasis and tumor growth [11] .
The gene encoding I-branching b-1,6-N-acetylglucosaminyltransferase 2 (GCNT2), formerly named IGnT, is one such glycan-related gene. The blood group I antigen is known to be the glycan product of GCNT2. GCNT2 is involved in tumor growth factor b (TGFb)-induced EMT of breast cancer cells [12] . GCNT2 is substantially upregulated in EMT, and in vitro studies have demonstrated that its upregulation enhances cell detachment, adhesion to endothelial cells, cell migration, and invasion, and thus GCNT2 promotes EMT of breast cancer cells in vivo and their subsequent metastasis to lung [12] .
The mechanism by which GCNT2 is induced upon EMT in cancer cells has not been fully elucidated. A previous investigation [12] suggested that GCNT2 is induced upon EMT as a direct target of the TGFbSmad pathway, especially the pathway involving Smad2, and proposed that blocking TGFb/GCNT2 signaling is a promising approach for targeting metastatic breast cancer. Although TGFb was used to induce EMT in that study of breast cancer cells, here we employed treatment with epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) [10] instead of TGFb to induce EMT in colon cancer cells, in which TGFb receptors are frequently mutated. MicroRNAs (miRNAs) are endogenous~22-nt RNAs that can play important regulatory roles by targeting mRNAs for degradation or translational repression, and miRNAs are well recognized as critical post-transcriptional regulators of gene expression in cancer cells [13] [14] [15] [16] [17] [18] . Target genes of miRNAs frequently include glycan-related genes [19, 20] , and our present results strongly implicate the involvement of miRNAs, especially the miR-199 family, in the induction of GCNT2 upon EMT in colon cancer cells.
Material and methods

Cell lines and cell culture
Cultured human colon cancer cell lines DLD-1, LoVo, and SW480, and human embryonic kidney cells, 293T, were maintained at 37°C with 5% CO 2 streptomycin (Invitrogen) as described [10] .
Migration and invasion assays
For migration assays, cells (DLD-1; 2. (Table S2) . First-strand cDNA for each miRNA was prepared from total RNA (10 ng) with the Universal cDNA synthesis kit II (EXIQON, Vedbaek, Denmark). For qPCR of miRNA, cDNA samples were mixed with ExiLENT SYBRÒ Green master mix (EXIQON) and microRNA LNA TM primers (Table S3 ). The amplification for all qPCRs was monitored using the CFX Connect Real-Time PCR System (Bio-Rad). Relative transcript levels were calculated as 2 ÀDDCT .
Flow cytometry
Cells were harvested and incubated with purified primary antibody directed to I antigen (antibody C6) [21] . The cells were then stained with APC-conjugated secondary antibody (Biolegend, San Diego, CA, USA, RMM-1) and analyzed with a FACSCalibur (BD Biosciences, San Jose, CA, USA).
Western blotting
Whole-cell extracts were prepared with RIPA buffer (Sigma) containing protease and phosphatase inhibitors (Roche, Mannheim, Germany). Proteins in the extracts were separated by SDS/PAGE, followed by transfer to a polyvinylidene difluoride membrane (GE Healthcare, Chicago, IL, USA). After blocking with 5% skim milk, each membrane was incubated with a primary antibody and a horseradish peroxidase-conjugated secondary antibody (Jackson Lab). The signal was detected with the ECL kit (GE Healthcare) and analyzed with the Biospectrum 500 imaging system (UVP). Antibodies against AKT (pan) (11E7; #4685), phosphorylated AKT (p-AKT, Ser473; #9271), ERK1/2 (137F5; #4695), p-ERK1/2 (20G11; #4376), Src (32G6: #2123), and p-Src family (Tyr416; #2101), Snail1 (C15D3), and ZEB1 (D80D3) were obtained from Cell Signaling Technology, and the antibody against GCNT2 isoform A (HPA026776) was from Sigma. Antibodies against E-cadherin (GTX100443), vimentin (EPR3776), TWST1 (GTX127310), and fibronectin (GTX1127954) were obtained from GeneTex (Irvine, CA, USA).
GCNT2 knockdown and forced expression
The pLKO.1-based lentivirus encoding a short hairpin RNA (shRNA) against GCNT2 and a scrambled-sequence shRNA (control) were obtained from the National RNAi Core Facility, Academia Sinica. The infection and selection protocol were described previously [10] . For knockdown of GCNT2, TRCN0000004933 (sh-33) and TRCN0000004936 (sh-36) gave the best results among five tested shRNA vectors. For forced expression of GCNT2 [22] or miR-199a/b, the cDNAs were cloned into Trip-GFP or pll3.7 vector, respectively. Trip-GFP, pll3.7, packaging (pMD2.G), and envelope (psPAX2) vectors were obtained from Addgene (Cambridge, MA, USA). Virus production and infection followed published protocols [10] . The infected cells expressed GFP as a fluorescent indicator and were sorted with a FACSAria (BD Biosciences).
Cell proliferation assay
Cells (DLD-1; 5 9 10 
Reporter constructs and luciferase assays
The full-length 3 0 untranslated region (UTR) of GCNT2
was prepared from colon cancer cell cDNA and was cloned into the 3 0 UTR of the firefly luciferase reporter gene in pGL4.13 (Promega). For reporter assays, cells were cotransfected with the firefly luciferase constructs, pRL-tk renilla luciferase plasmid (Promega, Madison, WI, USA), and miRNA expression vectors (miR-30a, miR-30b, miR30c, and miR-135a were gifts from the National RNAi Core Facility, Academia Sinica). After 48 h, luciferase activity was measured using the Dual-Luciferase Reporter Assay System kit (Promega).
RNA-induced silencing complex-trap assays
The RISC-trap assays were performed with the MirTrap system (Clontech, Mountain View, CA, USA). This assay is based on stabilization of the RISC/miRNA/target mRNA complex by introducing a dominant-negative mutant GW182, which is a core component of RISC complex [23] . Dominant-negative mutant GW182 (dnGW182) still retains binding ability to the complex but loses its capacity to recruit effectors, thus can no more degrade targeted mRNA or inhibit targeted mRNA translation. Briefly, the cells were cotransfected with the miRNA mimics, dnGW182 (fused with a flag tag), and dual fluorescence indicator. The dual fluorescence indicator contains a miR-132 binding site on Aequorea coerulescens GFP (AcGFP) and constitutively expresses DsRed (Discosoma sp. red fluorescent protein; as a transfection control), and is to be cotransfected with miR-132 mimic. After 48 h, we lysed the cells and captured the complex by RNA coimmunoprecipitation with anti-flag-coupled beads. Then, mRNA was eluted from the RISC/miRNA/target mRNA complex on anti-flag-coupled beads by NucleoSpin RNA XS Kit according to the manufacturer's protocol (Clontech). The purified mRNA was subjected to one-step real-time PCR (QIAGEN, Hilden, Germany) to evaluate the presence of binding targets. In this assay, AcGFP (with a miR-132 binding site) acted as the positive quality control and Plod3 (without any miR-132 binding site) as the negative quality control, when cotransfected with miR-132 mimic. The cotransfection of dnGW182 with miR-199 mimic will trap the GCNT2 mRNA to prove the direct binding of miR-199 to GCNT2. Statistical analysis PRISM 6 software (GraphPad, La Jolla, CA, USA) was used for statistical analysis. Potential statistical differences between two groups were assessed with the Student's t-test (two-tailed). All results are presented as the mean AE SEM.
In vivo tumor xenograft experiments
A P-value of less than 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
EGF-and bFGF-mediated induction of EMT in cultured human colon cancer cells
To induce EMT in colon cancer cells, we cultured DLD-1 and LoVo cells in serum-free DMEM/F12 medium supplemented with 20 ngÁmL À1 EGF and 10 ngÁmL À1 bFGF [10] . This treatment induced morphological changes from an epithelial-like to spindlelike fibroblastic cell shape (Fig. 1A,B) . The treated cells displayed increased migration and invasion compared with untreated control cells (Fig. 1C,D) . EGF/ bFGF treatment reduced the level of the epithelial marker E-cadherin and increased the levels of the mesenchymal markers vimentin, fibronectin, SNAIL 1, TWIST 1, and ZEB 1 (Fig. 1E,F) . These results indicated that EMT was induced by treating DLD-1 and LoVo cells with EGF/bFGF.
Induction of cell surface I antigen is associated with EMT of colon cancer cells
We next assessed whether the levels of glycans having Ibranching structures ( Fig. 2A) were increased in association with EMT of colon cancer cells. We used flow cytometry with an I antigen-specific monoclonal antibody (C6) to evaluate I antigen levels on the surface of cells undergoing EMT. The epitope recognized by C6 is shown in Fig. 2B . Treatment of cells with EGF/bFGF significantly increased the levels of I antigen compared with parental control cells (Fig. 2C ). GCNT2 synthesizes I antigen, and so we assessed the mRNA levels of three GCNT2 isoforms using qPCR with TaqMan probes. The levels of all three mRNA isoforms increased after induction of EMT, and isoform A predominated in colon cancer cells (Fig. 2D) . We also used western blotting to determine the isoform A level, revealing that the level in treated cells was dramatically increased compared with that in parental control cells (Fig. 2E) . These results indicated that treatment with EGF and bFGF could strongly induce cell surface expression of I antigen by upregulating both the mRNA and protein levels of GCNT2, particularly those of isoform A.
GCNT2 overexpression in colon cancer cells enhances their malignancy-related characteristics
To determine the functional significance of GCNT2 expression in colon cancer cells, we established DLD-1 cells stably overexpressing GCNT2 isoform A (Fig. 3A) .
The overexpressing cells grew significantly faster than control cells and exhibited a dramatic increase in cell migration and invasion (Fig. 3B,C) . Western blotting for components of cell signaling pathways in GCNT2 isoform A-overexpressing DLD-1 cells revealed increased levels of p-AKT, p-ERK1/2, and p-Src (Fig. 3D) . Overexpression of isoform A also significantly increased the levels of I antigen by 5.6-fold (Fig. 3E) . These results indicated that GCNT2 contributes to the oncogenic properties of colon cancer cells.
Knockdown of GCNT2 in colon cancer cells suppresses their malignancy-related characteristics
To assess the effects of experimental downregulation of GCNT2 in colon cancer cells, we established two GCNT2 isoform A knockdown lines of SW480 cells. The levels of GCNT2 were markedly reduced in both clones as ascertained by RT-qPCR and western blot (Fig. 4A,B) . We then evaluated cell proliferation for these stably knocked-down lines (Fig. 4C) . The proliferation curves indicated that GCNT2 knockdown markedly inhibited the proliferation of both clones. Clone shGCNT2-36 had greater knockdown efficiency and decreased the cell proliferation more so than clone shGCNT2-33 (Fig. 4C) . The migration and invasion assays of clone shGCNT2-36 revealed significantly reduced migration and invasion compared with the scrambled-sequence control shRNA clone (Fig. 4D) . We next explored whether GCNT2 knockdown affected the levels of components of the AKT and ERK signaling pathways. Western blotting of extracts of knockdown cells revealed decreased levels of p-AKT, p-ERK1/2, and p-Src (Fig. 4E) . Finally, we found that GCNT2 knockdown resulted in an 83% decrease in cell surface I antigen as determined with flow cytometry (Fig. 4F) . These results suggested that GCNT2 knockdown counters the oncogenicity of colon cancer cells.
Screening for potential miRNAs that regulate GCNT2 expression
When we examined the mRNA levels of the three GCNT2 isoforms in colon cancer cells, we noticed that not only isoform A but also the minor isoforms B and C showed a similar degree of induction upon EMT (Fig. 2D, insets) . Isoforms B and C are encoded by an exon 1 that is quite different from that of isoform A, and these two isoforms have quite different 5 0 -regulatory regions compared with isoform A, although they share the same 3 0 UTR [22] . The similar fold induction observed for isoforms A-C upon EMT suggested that post-transcriptional regulation targeting the common 3 0 UTR, such as by a miRNA(s), may be involved in the induction of GCNT2 upon EMT.
To test the hypothesis that specific miRNAs may participate in regulating GCNT2 expression, we first cloned the full-length GCNT2 3 0 UTR (including forward and reverse orientations; Fig. 5A ) into vector pGL4.13 and transfected these plasmids individually into DLD-1 and LoVo cells. In reporter assays, the relative luciferase activity of GCNT2 3 0 UTR fulllength forward orientation was significantly attenuated compared with pGL4.13 vector only or GCNT2 3 0 UTR full-length reverse orientation (Fig. 5B) , suggesting that the GCNT2 3 0 UTR might be regulated by miRNAs in colon cancer cells.
Next we used the online software TARGETSCAN potentially regulate GCNT2 level. To explore which miRNA was the most potent regulator, we transfected 293T cells with these three miRNAs along with the GCNT2 3 0 UTR full-length forward orientation vector. The reporter assays revealed that miR-199a/b-5p was the most potent regulator of GCNT2 (Fig. 5C ).
Treatment of colon cancer cells with EGF and bFGF alters the expression of miR-199a/b-5p upon EMT
We evaluated the expression of miR-199a/b-5p in colon cancer cells undergoing EMT and found that the level in the EGF/bFGF-treated cells was markedly decreased compared with control cells as ascertained by miRNA RT-PCR (Fig. 5D) . These results were in line with the idea that miR-199a/b-5p downregulation upon EMT may be associated with the observed induction of GCNT2 expression.
Reporter assays reveal that miR-199a/b-5p targets GCNT2 in colon cancer cells
According to the prediction of TargetScan, miR-199a/ b-5p has two potential target sites in the GCNT2 3 0 UTR, and both complementary sequences are evolutionarily conserved (Fig. 6A,B) . Results of reporter assays revealed that overexpression of miR-199a-5p or miR-199b-5p attenuated luciferase activity in a dosedependent manner (Fig. 6C) . Conversely, transfection of DLD-1 cells with an antisense inhibitor of miR199a-5p or miR-199b-5p led to a significant increase in luciferase activity (Fig. 6D) . To assess which targeted site(s) within the GCNT2 3 0 UTR was the major site for repression, we generated three deletion constructs of the 3 0 UTR sequence in which the sites targeted by miR-199a/b-5p were altered (Fig. 6E) . The reporter assays indicated that GCNT2 wild-type (full-length GCNT2 3 0 UTR) had the strongest repression activity in both DLD-1 and LoVo cells. Compared with GCNT2 wild-type, GCNT2 D2 (having a deletion in the targeting site 2 sequence) and GCNT2 D1 + 2 (having a deletion in both targeting site 1 and 2 sequences) could abrogate repression. However, GCNT2 D1 (having a deletion in the targeting site 1 sequence) only slightly affected repression (Fig. 6F) . These results indicated that the binding site 2 in the GCNT2 3 0 UTR is the most crucial for regulation by the miR-199 family.
RISC-trap assays reveal that miR-199a/b-5p directly targets GCNT2 in colon cancer cells
To confirm that GCNT2 3 0 UTR is a direct target of miR-199a-5p and miR-199b-5p, a RISC-trap assay was used to investigate the interaction between the miR-199 family and the RISC complex targeted to GCNT2 mRNA. For the RNA coimmunoprecipitation fractions from SW480-miR-132 cells, AcGFP served as a positive control and Plod3 as a negative control. According to coimmunoprecipitation results, AcGFP mRNA was significantly enriched (fold increase, 6.36 AE 0.16) compared with the sample before immunoprecipitation, whereas Plod3 mRNA was not significantly different (fold difference, only 1.27 AE 0.29) in these two samples (Fig. 7A) . The miR-132-3p transfection efficiency was evaluated with miRNA qPCR (Fig. 7B) . As expected, GCNT2 mRNA was notably enriched in SW480-miR-199a-5p cells and SW480-miR-199b-5p cells (4.35 AE 0.26 fold, and 5.9 AE 0.49 fold, respectively; Fig. 7C ). The miR-199a-5p and miR-199b-5p transfection efficiencies were also ascertained by miRNA qPCR (Fig. 7D) . Taken together, these results indicated that the miR-199 family directly targets the GCNT2 3 0 UTR to regulate cellular GCNT2 level.
Downregulation of GCNT2 and I antigen by constitutive expression of miR-199a and miR-199b
When stable cell lines constitutively expressing miR199a or miR-199b were generated from DLD-1 cells (Fig. 8A) , the levels of both GCNT2 mRNA and protein were reduced markedly (Fig. 8B,C) . The migration and invasion capacities of the cells were also decreased (Fig. 8D) . The expression of I antigen was attenuated by overexpressing miR-199a or miR-199b (Fig. 8E) . These results were similar to what observed for GCNT2 knockdown cells (Fig. 4D,F) . The in vitro proliferation curves indicated that constitutive expression of miR-199a or miR-199b inhibited proliferation of DLD-1 cells (Fig. 8F ). Marked reduction in tumor volume was observed in DLD-1 cells expressing miR199a or miR-199b compared to those expressing miRcontrol in in vivo xenograft experiments (Fig. 8G ). These findings indicated that GCNT2 is a direct target of regulation by the miR-199 family in colon cancer cells and suggested that the induction of GCNT2 upon EMT is at least partly due to EMT-induced downregulation of miR-199.
Discussion
There are two major findings of the present study: (i) Expression of the N-acetylglucosaminyltransferase GCNT2 and its product, I antigen, is strongly induced during EMT by EGF and bFGF treatment of colon cancer cells, and (ii) the miR-199 family plays a key role in this process. Cancer cells undergo drastic changes in the repertoire of their cell surface glycans during their tumorigenic progression, with concomitant changes in the cellular transcription program and post-transcriptional regulation [24] [25] [26] [27] [28] [29] [30] [31] . Certain glycans that are frequently found in cancers can be utilized as diagnostic markers. Some of these glycans function as ligands for vascular selectins that facilitate hematogenous metastasis, or as ligands for cell surface/sialic acid-binding proteins, siglecs, that suppress immune function [24, 25, 32] . Because GCNT2 is involved in the synthesis of branches in the basic structure of polylactosamines, the enzyme is thought to increase the valency of the epitopes that are exposed at the surface of the glycans [33] . The biological significance of I-branched polylactosamines had been obscure because it has been thought to depend on which structures are synthesized at the terminal regions of the branched glycans in given cells and tissues [33] . For instance, if components of the ABO(H) blood group system are added to the terminal glycan structures, increased valency of the ABO(H) antigenic epitopes would be expected for glycan products of GCNT2, whereas if selectin ligands are added at the terminus, cancer cell adhesion to endothelial cells would be expected to be enhanced. The results of recent studies that incorporated molecular biological approaches have provided evidence for distinct functions for the genes involved in the synthesis of basic glycan structures. In particular, several glycanrelated genes that are induced upon EMT were recently described to have key functions in promoting EMT. For instance, FUT8, which is involved in the synthesis of the basic glycan structure, is induced upon EMT of cancer cells, and FUT8 activation promotes cancer cell motility Reduction in cell surface I antigen in DLD-1 cell lines stably transfected with miR-199a-5p or miR-199b-5p as ascertained by flow cytometry using antibody C6 that recognizes I antigen. (F) Decreased in vitro proliferation of DLD-1 cell lines stably transfected with miR-199a-5p or miR-199b-5p (***P < 0.001). (G) Decreased in vivo tumor growth of DLD-1 cell lines stably transfected with miR-199a-5p or miR-199b-5p in xenograft model using immunodeficient mice (each group contained five mice) (**P < 0.01, ***P < 0.001).
and invasiveness [11] . GCNT2 is one such glycan-related gene that is induced upon EMT of cancer cells. Our overexpression and knockdown experiments clearly demonstrate that GCNT2 has cancer-promoting functions such as enhancing cell motility and invasiveness not only in colon cancer cells (this study) but also in breast cancer cells [12] and prostate cancer cells [34] , and thus GCNT2 promotes tumorigenesis independently of cancer type.
In the present study, we demonstrate that all three GCNT2 isoforms are dramatically upregulated (with concomitant enhanced cell surface I antigen) upon EMT of colon cancer cells (Fig. 2) . We found that GCNT2 not only synthesizes I antigen but also enhances the proliferation, migration, and invasion of colon cancer cells. Our results show that cancerinduced upregulation of GCNT2 activates AKT and ERK signaling (Figs 3 and 4) . It has been reported that activation of AKT and ERK signaling affects a variety of cellular functions including survival, proliferation, migration, and invasion [35, 36] . These findings raise intriguing issues about the possible role of GCNT2 in modulating AKT and ERK signaling.
In recent years, post-transcriptional regulation has been demonstrated as a key process during cancer progression. The miRNAs that post-transcriptionally regulate gene expression have been reported to suppress the progression of diverse cancer types [37] [38] [39] , and miRNAs are known to regulate various glycan-related genes [19, 20] . We demonstrated that the miR-199 family plays a dominant role in regulating GCNT2 level upon EMT of colon cancer cells. The miRNAs miR-9, miR-495, miR-30a, miR-17-3p, miR-145, miR-194, miR-124, and miR-200 have been shown to be involved in EMT of cancer cells [37, 39] . The involvement of miR-199 in EMT is less frequently studied compared with the other miRNAs that are typically associated with EMT; still, miR-199 has been reported to be downregulated during EMT and thus affects the oncological properties of cancer cells [40, 41] . Our results demonstrate that miR-199 is markedly downregulated upon EMT of colon cancer cells (Fig. 5) , which is concordant with these previous findings.
The 3 0 UTR of GCNT2 contains evolutionarily conserved miR-199-binding sites as assessed in silico (Fig. 6 ). Our results demonstrate that the miR-199 family strongly inhibits GCNT2 in reporter assays (Fig. 6 ) and that family members intracellularly bind to GCNT2, as shown by MirTrap assays (Fig. 7) . Moreover, miR-199 family overexpression reduces the levels of GCNT2 and its product I antigen and inhibits cancer cell motility and invasion (Fig. 8) . These results strongly suggest that downregulation of miR-199 is at least partly responsible for the observed induction of GCNT2 upon EMT of colon cancer cells. Consistent with these results, the levels of miR-199 family members are downregulated in metastatic lesions in contrast with the primary tumor as seen in clinical samples of colon cancers, and miR-199 suppresses colon cancer metastasis in vivo [42] [43] [44] [45] [46] . It has been suggested that the miR-199 family regulates the progression and metastasis of various cancers other than colon cancer, including liver, ovarian, prostate, and breast cancers [47] [48] [49] [50] [51] .
In a previous report, GCNT2 was suggested to be a direct target of the TGFb-Smad pathway [12] . The major difference between this report and ours is that TGFb was used to induce EMT in that previous study, whereas we used a combination of EGF and bFGF. Another group proposed that GCNT2 is regulated by DNA methylation [52] . GCNT2 isoform A is the major isoform in epithelial cancer cells, whereas isoform C predominates in erythroid cells [22] . Transcription factor C/EBPa has been proposed to play a major role in the regulation of the expression of isoform C in differentiation of normal erythroid cells [53, 54] . Further studies must determine which plays the dominant role in the regulation of GCNT2 upon EMT of cancer cells. 
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